Antimicrobial activity against a global collection of skin and skin structure pathogens: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.
Int J Infect Dis. 2016 Jun 22;
Authors: Tärnberg M, Nilsson LE, Dowzicky MJ
BACKGROUND: As part of the Tigecycline Evaluation and Surveillance Trial we report antimicrobial resistance among Gram-positive and Gram-negative isolates collected globally from integumentary sources between 2010 and 2014.
METHODS: Minimum inhibitory concentrations and antimicrobial resistance were determined according to Clinical and Laboratory Standards Institute guidelines (US Food and Drug Administration breakpoints against tigecycline). The Cochran Armitage Trend Test was used to identify statistically significant changes in resistance.
RESULTS: Global rates of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii were 38% and 43% respectively. No S. aureus isolates were resistant to linezolid or vancomycin; all isolates were susceptible to tigecycline. 2% of Enterococcus faecalis and 28% of Enterococcus faecium were vancomycin-resistant. Extended-spectrum β-lactamase (ESBL) producers accounted for 22% of Klebsiella pneumoniae and 16% of Escherichia coli. Resistance to minocycline among E. faecalis, E. faecium, K. pneumoniae and E. coli decreased significantly (p<0.0001). There were significant increases (p<0.0001) in A. baumannii resistance to cefepime, ceftazidime, ceftriaxone, levofloxacin, meropenem and piperacillin-tazobactam.
CONCLUSIONS: Among isolates from integumentary sources rates of MRSA and ESBL-producing Enterobacteriaceae are stabilizing. Carbapenems and tigecycline retained their in vitro activity against Gram-positive and Gram-negative organisms. Few agents were active against A. baumannii; its increasing resistance is cause for concern.
PMID: 27343986 [PubMed - as supplied by publisher]